Roche’s pTau217 single-biomarker Alzheimer’s blood test lands FDA approval
August 24, 2026
FDA clearance for Roche’s pTau217 follows the blood-based test’s receipt of a European CE mark in May 2026.
FDA clearance for Roche’s pTau217 follows the blood-based test’s receipt of a European CE mark in May 2026.